In particular, the development of rat models with human CF-causing variants introduced into the CFTR gene such as Phe508del provides the opportunity to test mutation-specific therapies in vivo including CFTR modulators, antisense oligonucleotides, and gene editing strategies [4, 5]. Here, CFTR is linked to cystic fibrosis.